Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of the CCKB antagonist CI-988 on responses to mCPP in generalized anxiety disorder
Autore:
Goddard, AW; Woods, SW; Money, R; Pande, AC; Charney, DS; Goodman, WK; Heninger, GR; Price, LH;
Indirizzi:
YaleUSAiv, Dept Psychiat, Connecticut Mental Hlth Ctr, New Haven, CT 06519Yale Univ New Haven CT USA 06519 cut Mental Hlth Ctr, New Haven, CT 06519 Warner Lambert Co, Parke Davis Pharmaceut Res Div, CNS, Ann Arbor, MI 48015 Warner Lambert Co Ann Arbor MI USA 48015 es Div, CNS, Ann Arbor, MI 48015 Univ Florida, Coll Med, Dept Psychiat, Gainesville, FL 32610 USA Univ Florida Gainesville FL USA 32610 Psychiat, Gainesville, FL 32610 USA BrownUSAiv, Dept Psychiat & Human Behav, Butler Hosp, Providence, RI 02906Brown Univ Providence RI USA 02906 hav, Butler Hosp, Providence, RI 02906
Titolo Testata:
PSYCHIATRY RESEARCH
fascicolo: 3, volume: 85, anno: 1999,
pagine: 225 - 240
SICI:
0165-1781(19990322)85:3<225:EOTCAC>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
M-CHLOROPHENYLPIPERAZINE MCPP; B RECEPTOR ANTAGONISTS; ELEVATED PLUS-MAZE; PANIC DISORDER; CHOLECYSTOKININ-TETRAPEPTIDE; META-CHLOROPHENYLPIPERAZINE; HEALTHY-VOLUNTEERS; SEROTONIN FUNCTION; 5-HT3 ANTAGONIST; RAT;
Keywords:
anxiety; serotonin; cholecystokinin; m-chlorophenylpiperazine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Life Sciences
Citazioni:
58
Recensione:
Indirizzi per estratti:
Indirizzo: Goddard, AW Yale Univ, Dept Psychiat, Connecticut Mental Hlth Ctr, 34 Pk St, New Haven, Yale Univ 34 Pk St New Haven CT USA 06519 34 Pk St, New Haven,
Citazione:
A.W. Goddard et al., "Effects of the CCKB antagonist CI-988 on responses to mCPP in generalized anxiety disorder", PSYCHIAT R, 85(3), 1999, pp. 225-240

Abstract

In order to evaluate the effect of the CCK, antagonist CI-988 on behavioral, neuroendocrine, and physiologic responses to the mixed, post-synaptic serotonin (5-HT) agonist/antagonist mCPP, 16 patients with a principal DSM-III-R diagnosis of generalized anxiety disorder (GAD) were enrolled in a study that involved two challenge tests. On one day, patients received a singleoral dose of CI-988 followed 30 min later by an i.v. infusion of 0.1 mg/kgmCPP. On a second test day patients received placebo CI-988 followed 30 min later by active i.v. mCPP. The sequence of CI-988 was randomly assigned and the testing was conducted in double-blind fashion. In an initial dose-finding phase (N = 6) with a dose of CI-988 of 25 mg, there were no significant between-test differences in behavioral response to mCPP. Accordingly, the second phase of the study was conducted with a CI-988 dose of 100 mg in another of patients (N = 10). CI-988 (100 mg) was well tolerated and had no significant effects on pretest anticipatory anxiety. There was no significant blunting of the anxiety response to mCPP as a result of CI-988 administration, nor did CI-988 affect physiologic or neuroendocrine measures. Correlations between peak changes in plasma levels of CI-988 and mCPP-induced anxiety in the high-dose patient group were not significant. Overall, these findings did not provide evidence of anxiolytic effects of CI-988 in patientswith GAD. The lack of effect of CI-988 on neuroendocrine and physiologicalmeasures further suggests that CI-988's pharmacological effects could be independent of 5-HT function. However, follow-up studies using higher doses of CI-988 are indicated to confirm this preliminary finding as are studies more closely evaluating the interrelationship between CCK and 5-HT functionin GAD. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 00:42:37